好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Unique Patterns of Comorbidities in Pediatric Onset vs. Adult Onset Multiple Sclerosis Using a Large Real-world MS Population
Multiple Sclerosis
MS and CNS Inflammatory Disease Posters (7:00 AM-5:00 PM)
120

To define comorbidity patterns in a large, real world population of pediatric (POMS) and adult onset multiple sclerosis (AOMS) patients matched by disease duration. 

POMS comorbidity patterns, as captured in a large real world MS population, have not been reported and may effect disease severity. Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS) is a multi-center initiative sponsored by Biogen in which comorbidities, sociodemographics, NeuroOL, phenotype and  MS performance measures are collected longitudinally.
 

MS PATHS data cut 11 (March 2020) was evaluated. Patients with AOMS and POMS were matched 5:1 based on disease duration. Rates of medical and psychological comorbidities were compared through Chi-Squared test  or Wilcoxon Mann Whitney Rank Sum Test. Linear regression was used to determine what predicted comorbidity presence. 

 

 

 A total of 14,878 patients were identified. After matching, there were 3,455 AOMS (mean age 51.2, 63% white, mean dx age 35) vs 690 POMS (mean age 35.7, 40% white, mean dx age). There was no significant difference between the cohorts in mental health comorbidities, COPD or dyslipidemia even though smoking was significantly more common among those with AOMS. There were significant differences in the groups with respect to diabetes (p=.0075, 4 vs 44% ) and cardiac comorbidities (p=<0.0001) 19 vs 42%). Measures that predicted depression included: age, smoking status, sleep, fatigue, anxiety, disease stigma, and upper and lower extremity function.  Measures that predicted anxiety included: sex, race, insurance type, patient reported disability level, sleep, depression, fatigue, walking speed, and disease stigma.


POMS had similar rates of mental health and some medical comorbidities despite younger median age.  POMS  had lower rates of smoking, cardiac and diabetes.  Mental health comorbidities in both groups were predicted by demographic, functional, and quality of life outcomes. Prevention, improved detection and treatment of comorbidities is important in both POMS and AOMS.

Authors/Disclosures
Mary R. Rensel, MD, FAAN
PRESENTER 		Dr. Rensel has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Rensel has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for genentech. Dr. Rensel has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis . Dr. Rensel has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for EMD Serono. Dr. Rensel has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for TG. Dr. Rensel has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for biogen. Dr. Rensel has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Genentech. Dr. Rensel has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Sanofi. Dr. Rensel has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for EMD Serono. Dr. Rensel has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for TG. Dr. Rensel has stock in Brain Fresh LLC . The institution of Dr. Rensel has received research support from NMSS. The institution of Dr. Rensel has received research support from Roche- Genentech . The institution of Dr. Rensel has received research support from Biogen.
Devon Conway, MD Dr. Conway has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bristol Myers Squibb. Dr. Conway has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Conway has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentech. Dr. Conway has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Amgen. Dr. Conway has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Conway has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biogen. The institution of Dr. Conway has received research support from Novartis. The institution of Dr. Conway has received research support from BMS. The institution of Dr. Conway has received research support from Biogen.
Sarah M. Planchon Pope, PhD, CCRP (Cleveland Clinic) Dr. Planchon Pope has nothing to disclose.